Literature DB >> 22904123

Onco-nephrology: glomerular diseases with cancer.

Jean-François Cambier1, Pierre Ronco.   

Abstract

Glomerular diseases occurring in the course of malignancies remain rare. Diverse glomerular lesions can be observed in a variety of neoplasms and involve different pathophysiologic links between the glomerulopathy and the cancer. The pathophysiology of solid tumor-associated glomerulopathies remains obscure, whereas in hematologic malignancy-induced paraneoplastic glomerulopathies, a molecular link can usually be demonstrated. The aim of this review is to provide an update on glomerular diseases associated with carcinoma and hematologic malignancies, covering epidemiology, pathophysiology, clinical presentation, and therapy. Special emphasis will be placed on the potential usefulness of novel biomarkers, such as antiphospholipase A2 receptor antibodies, for the diagnosis of membranous nephropathy, and on new associations and recent entities, including (proliferative) GN with nonorganized monoclonal immunoglobulin deposits and myeloproliferative neoplasm-related glomerulopathy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22904123     DOI: 10.2215/CJN.03770412

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  33 in total

1.  Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.

Authors:  A Radice; F Pieruzzi; B Trezzi; G Ghiggeri; P Napodano; M D'Amico; T Stellato; R Brugnano; F Ravera; D Rolla; G Pesce; M E Giovenzana; F Londrino; V Cantaluppi; F Pregnolato; A Volpi; G Rombolà; G Moroni; G Ortisi; Renato A Sinico
Journal:  J Nephrol       Date:  2017-10-28       Impact factor: 3.902

Review 2.  Immunopathogenesis of idiopathic nephrotic syndrome with relapse.

Authors:  Djillali Sahali; Kelhia Sendeyo; Melanie Mangier; Vincent Audard; Shao Yu Zhang; Philippe Lang; Mario Ollero; Andre Pawlak
Journal:  Semin Immunopathol       Date:  2014-01-09       Impact factor: 9.623

3.  A retrospective study of proteinuria in dogs receiving toceranib phosphate.

Authors:  Sindy L Piscoya; Kelly R Hume; Cheryl E Balkman
Journal:  Can Vet J       Date:  2018-06       Impact factor: 1.008

Review 4.  Kidney diseases associated with haematological cancers.

Authors:  Anirban Ganguli; Deirdre Sawinski; Jeffrey S Berns
Journal:  Nat Rev Nephrol       Date:  2015-06-02       Impact factor: 28.314

5.  Monoclonal B lymphocytosis and minimal change disease: a new monoclonal B-cell disorder of renal significance?

Authors:  Margaux Van Wynsberghe; Pascal Lenain; Fanny Drieux; Dominique Guerrot; Dominique Bertrand
Journal:  J Nephrol       Date:  2017-12-21       Impact factor: 3.902

6.  Screening for Cancer in Patients with Glomerular Diseases.

Authors:  Emmanuelle Plaisier; Pierre Ronco
Journal:  Clin J Am Soc Nephrol       Date:  2020-02-04       Impact factor: 8.237

Review 7.  Noncardiovascular mortality in CKD: an epidemiological perspective.

Authors:  Dinanda J de Jager; Marc G Vervloet; Friedo W Dekker
Journal:  Nat Rev Nephrol       Date:  2014-02-04       Impact factor: 28.314

8.  Hypertensive nephropathy is associated with an increased risk of myeloma, skin, and renal cancer.

Authors:  James Goya Heaf; Alastair Hansen; Gunnar Hellmund Laier
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-05-24       Impact factor: 3.738

9.  NELL1 is a target antigen in malignancy-associated membranous nephropathy.

Authors:  Tiffany N Caza; Samar I Hassen; Zeljko Dvanajscak; Michael Kuperman; Rick Edmondson; Christian Herzog; Aaron Storey; John Arthur; L Nicholas Cossey; Shree G Sharma; Daniel J Kenan; Christopher P Larsen
Journal:  Kidney Int       Date:  2020-08-20       Impact factor: 10.612

10.  Cryofibrinogen-associated glomerulonephritis accompanied by advanced gastric cancer.

Authors:  Kota Kakeshita; Hidenori Yamazaki; Teruhiko Imamura; Takayuki Ando; Shiori Kobayashi; Hayato Fujioka; Tsutomu Koike; Akira Shimizu; Koichiro Kinugawa
Journal:  CEN Case Rep       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.